Veracyte, Inc.
VCYT Nasdaq· Services-Medical Laboratories
Last close · Oct 23, 2026
$47.93
KIRA · Stoqly’s AI analyst, in plain words
- Veracyte, Inc. had $517M of revenue in fiscal 2025, up 16.0% on the year before. Over five years, revenue changed +34.5% a year on average.
- Its operating margin was 11.2%, up 7.6 pts: of every 100 in sales, about 11 is left after running the business.
- Veracyte, Inc. made $66.4M of net profit in fiscal 2025.
- Free cash flow was $127M in fiscal 2025, 24.5% of revenue.
Market cap
$3.9B
P/E
34.2x
Revenue
$517M
Net income
$66.4M
Free cash flow
$127M
Operating margin
11.2%
Veracyte, Inc. in 30 seconds · fiscal 2025
Are sales growing?
+16.0%
Yes. Sales grew 16.0% last year.
Does it make a profit?
12.8%
Yes. It keeps 12.8% of every sale as profit.
Does profit turn into cash?
24.5%
Yes. 24.5% of sales ends up as free cash.
How healthy are the accounts?
7 / 8
Solid. It passes 7 of 8 health tests.
How is the share priced?
34.2x
One share costs 34.2 times its yearly profit per share.
What Veracyte, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 26, 2026
- Legal name
- VERACYTE, INC.
- CIK
- 0001384101
Veracyte, Inc. · VCYT
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $220M | $297M | $361M | $446M | $517M |
| Revenue growth | 86.8% | 35.1% | 21.8% | 23.5% | 16.0% |
| Gross margin | — | 59.2% | 63.6% | 66.9% | 70.1% |
| Operating margin | −37.3% | −13.9% | −23.8% | 3.6% | 11.2% |
| Net income | −$75.6M | −$36.6M | −$74.4M | $24.1M | $66.4M |
| Net margin | −34.4% | −12.3% | −20.6% | 5.4% | 12.8% |
| Diluted EPS | −$1.11 | −$0.51 | −$1.02 | $0.31 | $0.82 |
| Cash | |||||
| Cash from operations | −$31.6M | $7.5M | $44.2M | $75.1M | $136M |
| Capital expenditure | $5.4M | $8.5M | $10.0M | $11.3M | $9.7M |
| Free cash flow | −$37.0M | −$1.0M | $34.3M | $63.8M | $127M |
| FCF margin | −16.9% | −0.3% | 9.5% | 14.3% | 24.5% |
| Share count change | 27.5% | 5.4% | 1.5% | 7.6% | 3.1% |
| Debt and strength | |||||
| Cash and short-term investments | $173M | $154M | $216M | $239M | $413M |
| Debt incl. finance leases | $1.7M | $0.4M | — | — | — |
| Shareholders' equity | $1.1B | $1.1B | $1.0B | $1.2B | $1.3B |
| Current ratio | 3.8x | 4.0x | 4.7x | 4.7x | 8.1x |
| Returns and quality | |||||
| Return on capital | −7.0% | −3.5% | — | — | — |
| Return on equity | −10.0% | −3.4% | −7.0% | 2.2% | 5.3% |
| Return on tangible equity | −40.7% | −17.9% | −29.5% | 7.4% | 14.6% |
| Piotroski F-score | 3 | 6 | 5 | 7 | 7 |
| Altman Z'' | 12.2 | 13.6 | 14.9 | 10.4 | 15.7 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$21.1M
11 insiders
Of sales under plans
93%
$19.6M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Veracyte, Inc. · VCYT
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $47.93 a share, the company is worth $3.9B: 34.2 times its earnings of the last four quarters.
Source: SEC EDGAR XBRL filings (CIK 0001384101). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.